ArcaroliJ, QuackenbushK, DasariA, et al.Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer Med., 2012; 1:207–217.
2.
KendrewJ, OdedraR, LogiéA, et al.Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies. Cancer Chemother Pharmacol., 2013; 71:1021–1032.
GangadharTC, ClarkJI, KarrisonT, GajewskiTF. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs., 2013; 31:769–773.
